Mylan Recalls Valsartan Tablets Due to NDEA Impurity
Mylan is recalling Valsartan tablets because FDA analysis found trace amounts of the impurity N-nitrosodiethylamine (NDEA). The product was distributed throughout the United States.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe rating (Score 4) under the rubric for drug recalls involving potential health risks.
Plain-English summary
Mylan Laboratories Limited is recalling Valsartan Tablets, USP 160 mg, 90-count bottles. The recall involves 232,180 HDPE bottles of the prescription medication, which is manufactured in India for Mylan Pharmaceuticals, Inc. The product is identified by NDC 0378-5814-77 and specific lot numbers listed in the recall notice.
The recall was initiated because FDA analysis confirmed the presence of trace amounts of an impurity called N-nitrosodiethylamine (NDEA) in the active pharmaceutical ingredient (API) used to manufacture the product. NDEA is a potential carcinogen that is not permitted in pharmaceutical products at detectable levels.
The affected product was distributed throughout the United States to several major distributors, including Puerto Rico. Consumers and healthcare providers should check their inventory for the specific lot numbers and NDC codes listed in the official recall notice. If the product is found, it should be returned to the pharmacy or distributor for disposal or replacement.
The recalled product
- Product
- VALSARTAN (VALSARTAN)
- Brand
- VALSARTAN
- Manufacturer
- Mylan Laboratories Limited, (Nashik FDF)
- Category
- Drug — Prescription Medication
- Affected units
- 232,180
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot Numbers: 3069019
- 3069020
- 3069021
- 3069022
- 3071354
- 3071355
UPCs (4)
- 0303785815778
- 0303785813774
- 0303785807933
- 0303785814771
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 13 recalled by Mylan Laboratories Limited, (Nashik FDF) under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 13 products in this recall →Related recalls
Same brand · VALSARTAN
- ModerateCardinal Health Recalls Valsartan Tablets Due to Temperature Excursions
FDA (Drugs) · 2021-06-02
- SevereAurobindo Recalls Valsartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2019-03-27
- SevereAurobindo Pharma Recalls Valsartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2019-03-27
- SevereAurobindo Pharma Recalls Valsartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2019-03-27
- SevereAurobindo Recalls Valsartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2019-03-27
Same manufacturer · Mylan Laboratories Limited, (Nashik FDF)
See all →- SevereMylan Recalls Amlodipine and Valsartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2018-12-19
- HighMylan Recalls Amlodipine and Valsartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2018-12-19
- SevereMylan Recalls Valsartan and Hydrochlorothiazide Tablets Due to NDEA Impurity
FDA (Drugs) · 2018-12-19
- SevereMylan Recalls Valsartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2018-12-19
- SevereMylan Recalls Valsartan Tablets Due to Trace NDEA Impurity
FDA (Drugs) · 2018-12-19
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17